News related to Avastin (Bevacizumab) and/or conditions it is approved for
No Survival Benefit for Avastin in Glioblastoma (CME/CE)
Source: MedPage Today Radiology [2014.02.19]
(MedPage Today) -- First-line therapy for glioblastoma remained unchanged after two randomized trials showed no advantage to adding bevacizumab to the mix.
Avastin May Help Fight Early Breast Cancer
Source: MedicineNet capecitabine Specialty [2012.01.26]
Title: Avastin May Help Fight Early Breast Cancer
Category: Health News
Created: 1/26/2012 11:00:00 AM
Last Editorial Review: 1/26/2012 12:00:00 AM
Italian Watchdog Says Novartis, Roche Colluded Over Eye Drug
Source: Medscape Ophthalmology Headlines [2014.03.06]
Italy's antitrust authorities said Novartis and Roche colluded to try to stop cancer drug Avastin (bevacizumab) from being used to treat a serious eye disease, and fined the Swiss drugmakers 182.5 million euros ($251 million).
Reuters Health Information
Disappointing results from trial of bevacizumab for glioblastoma
Source: Cancer / Oncology News From Medical News Today [2014.03.04]
"The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizuman had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival.
Overall survival not improved by adding bevacizumab to initital glioblastoma treatment
Source: Radiology / Nuclear Medicine News From Medical News Today [2014.02.21]
Glioblastoma (GBM) is the most common primary malignant adult brain tumor and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months with few patients living beyond five years.